Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside By: Benzinga via Benzinga July 06, 2015 at 08:34 AM EDT In a report published Monday, H.C. Wainwright analyst Andrew S. Fein maintained a Neutral rating and $85 price target on Vertex ... Read More >> Related Stocks: Vertex Pharmaceuticals